8 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 7 with minor changes only.
Recruitment opened
Also in this update: Trial sites expanded: 0 → 7 locations
UCB Biopharma SRLPhase 3 NCT07465289 Registry history of NCT07465289 on ClinicalTrials.gov (opens the registry)
Trial status changed: Enrolling by Invitation → Active, Not Recruiting
Also in this update: Primary and study completion pushed from Aug 17, 2027 to Oct 5, 2027
UCB Biopharma SRLPhase 3 NCT06540144 Registry history of NCT06540144 on ClinicalTrials.gov (opens the registry)
Trial completed
UCB Biopharma SRLPhase 2/3 NCT06149559 Registry history of NCT06149559 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Sep 30, 2026 to Oct 31, 2026
UCB Biopharma SRLPhase 3 NCT05077904 Registry history of NCT05077904 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 9 → 13 locations
UCB Biopharma SRLPhase 2 NCT07725939 Registry history of NCT07725939 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 119 → 123 locations
UCB Biopharma SRLPhase 3 NCT04976322 Registry history of NCT04976322 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 11 → 14 locations
UCB Biopharma SRLPhase 3 NCT07463521 Registry history of NCT07463521 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 68 → 59 locations
And 1 more change in the last 30 days
UCB Biopharma SRLPhase 2 NCT07277660 Registry history of NCT07277660 on ClinicalTrials.gov (opens the registry)
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-09-30 | NCT07849894 A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of UCB0159 in… | Phase 1 | Completed |
| Phase 1 | 5 | |
| Phase 2 | 3 | |
| Phase 2/3 | 1 | |
| Phase 3 | 16 | |
| Phase 4 | 1 |
Myasthenia Gravis (6) · Psoriasis (6) · Epilepsy (5) · Psoriatic Arthritis (4) · Ankylosing Spondylitis (2) · Hidradenitis Suppurativa (2) · Lupus (SLE) (2) · Atopic Dermatitis (1) · COPD (1)